Potassium channels are essential in both excitable and non-excitable cells for the control of membrane potential, regulation of cell volume, and the secretion of salt, neurotransmitters and hormones. They are integral membrane proteins that allow the selective, diffusional passage of potassium ions across biological membranes, and are capable of up to 10,000-fold selectivity of potassium over sodium. With the sequencing of the human genome, over 80 potassium channel genes have now been identified, and can be grouped into several classes based on their transmembrane topologies. A vast pharmacology exists for potassium channels, including many peptide toxins isolated from venoms of various animals, as well as therapeutically more useful small organic compounds. Many of these agents act on multiple potassium channel subtypes, on account of the conserved structural elements among potassium channels, while others show potent specificity for a single channel subtype.

The inwardly-rectifying potassium channels have two transmembrane segments flanking the highly conserved P loop, which confers potassium selectivity, and assemble as tetramers. The two-P domain, or KCNK channels, consist of two inward recitifier-type domains linked together, and function as dimers. The voltage-gated and calcium-activated potassium channels have an inward rectifier-type topology preceded by four transmembrane domains (five, in the case of BK channels). A highly charged fourth transmembrane segment functions as the voltage sensor in the voltage-gated channels.

The N- and C-terminal domains of potassium channels are cytoplasmic and can regulate channel electrophysiological properties and trafficking, and can be a platform for phosphorylation, channel-lipid interactions, and co-assembly with other proteins. In addition to these pore-forming, or α-subunits, a number of cytosolic and transmembrane proteins co-assemble with potassium channels and can alter channel sensitivity to various ligands or to voltage, and can regulate subcellular localization of the channel complex.

While best known for their role in repolarizing the membrane of neurons and cardiomyocytes during an action potential, potassium channels are, in fact, expressed in all mammalian cell types, and even in lower organisms such as yeast, bacteria and viruses. They play a critical role in salt balance across epithelial cells, particularly in the kidney and colon. Two potassium channels, Kv1.3 and IKCa, are important for T cell signaling, proliferation and cytokine release, and the BK calcium-activated channel has recently been shown to be critical for neutrophil microbicidal activity. The ATP-inhibited, inwardly-rectifying potassium channel KATP, modulates insulin release by pancreatic β cells and is a major therapeutic target for treating type 2 diabetes.

In addition to KATP, a growing number of potassium channels are potential targets for treatment of diseases. For example, missense mutations in KCNQ2 or KCNQ3 that reduce M-channel current cause an autosomal dominant form of epilepsy, benign neonatal familial convulsions. In some forms of cancer, there is a correlation between overexpression of EAG or TASK3 and tumor cell proliferation.

High-resolution structures of several bacterial potassium channels are available, as well as cytoplasmic domains and β subunits of several mammalian channels. The determination of the structure of KcsA in 1998 showed the atomic details of potassium coordination by the selectivity filter. While the KcsA channel shows a channel in the closed state, the structure of the calcium-activated MthK revealed the conformation of an open channel. A structure of the voltage-gated potassium channel KvAP was published in 2003, but there is still much debate regarding the organization of transmembrane helices of this class of channels and the conformational changes involved in voltage gating. The increasing use of structural biology as a tool for studying ion channels will allow for more detailed understanding of disease-causing mutations, as well as the interactions between channels and the drugs that modulate them.

The Table below contains accepted modulators and additional information. For a list of additional products, see the "Materials" section below.

Footnotes

a) ATP-sensitive inward rectifier potassium channels are formed by the co-assembly of the Kir6.x channel, which constitutes the pore-forming unit, with the sulfonlyurea receptor (SUR).

b) The designations for voltage-sensitive potassium channels are quite imprecise. Molecular biological evidence demonstrates that both inactivating (A-type) and non-inactivating (delayed rectifier) channels belong to the same molecular family. Since functional channels consist of four potentially different α subunits, the possibility exists that there may be hundreds of different voltage-sensitive potassium channels, depending on their subunit composition.

c) Large conductance "maxi" or " BK" (big K) calcium-activated potassium channels display single channel conductances of 100-300 pS. The Kd for calcium varies with membrane potential and thus their activation is voltage-dependent. The voltage-insensitive, small conductance ("SK" ) and intermediate conductance ("IK") calcium-activated potassium channel have single channel conductance of < 20 pS and 20-80 pS, respectively.

d) Members of this family may combine to form the potassium current known as the M-current.

e) Slack/Slo2 is sodium-activated and calcium-insensitive, while Slo3 is pH-activated and calcium-insensitive.

f) Potency and specificity of the agents listed may vary according to subtype.

g) Most potassium channels are expressed in many different tissues. This list reflects tissues where various channel types are predominantly expressed and characterized.

Abbreviations

A-312110: (9R)-9-(4-Fluoro-3-iodophenyl)-2,3,5,9-tetrahydro-4H-pyrano[3,4-b]thieno [2,3-e]pyridin-8(7H)-one-1,1-dioxide
BMS-180448: (3S-trans)-N-(4-Chlorophenyl)-N′-cyano-N′′-(6-cyano-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl)
BMS-204352: (3S)-(+)-(5-Chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-6-(trifluoromethyl)-2H-indol-2-one)
BRL 55834: 1-[(3S,4R)-3,4-Dihydro-3-hydroxy-2,2-dimethyl-6-(pentafluoroethyl)-2H-1-benzopyran-4-yl]-2-piperidinone
CGS7184: 1-[[(4-Chlorophenyl)amino]carbonyl]-2-hydroxy-6-(trifluoromethyl)-1H-indole-3-carboxylic acid ethyl ester
CP 339818: 1-Benzyl-4-pentylimino-1,4-dihydroquinoline
DHS-1: Dihydrosoyasaporin-1
E-4031: 1-[2-(6-Methyl-2-pyridyl)ethyl]-4-(methylsulfonyl-aminobenzoyl)piperidine
HERG: Human ether-á-go-go related gene
LY-97241: N-Ethyl-N-heptyl-4-nitrobenzenebutanamine
MK-499: (+)-N-[1′ -(6-Cyano-1,2,3,4-tetrahydro-2(R)-naphthalenyl)-3,4-dihydro-4(R)-hydroxyspiro(2H-1-benzopyran-2,4â -piperidin)-6-yl]methanesulfonamide monohydrochloride
NS004: 5-Trifluoromethyl-(5-chloro-2-hydroxyphenyl)-1,3-dihydro-2H-benzimadole-2-one
NS309: 3-Oxime-6,7-dichloro-1H-indole-2,3-dione
NS1608: N-(3-(Trifluoromethyl)phenyl)-N′-(2-hydroxy-5-chlorophenyl)urea
NS1619: 1,3-Dihydro-1-[2-hydroxy-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-2H-benzimidazol-2-one
P-1075: N-Cyano-N′ -(1,1-dimethylpropyl)-N′′-3-pyridylguanidine
PNU-37883A: N-(1-adamantyl)-N'-cyclohexyl-4-morpholinecarboxamidine hydrochloride
RP 66471: 2-(Benzoyloxy)-N-methyl-1-(3-pyridinyl)-,(1S-trans)-cyclohexanecarbothioamide
SCA40: 6-Bromo-8-(methylamino)imidazo[1,2-a]pyrazine-2-carbonitrile
SCH 23390: R(+)-7-Chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride
SKF-525A: 2-Diethylaminoethyl-2,2-diphenylvalerate hydrochloride, Proadifen hydrochloride
TMB-8: 8-(Diethylamino)octyl 3,4,5-trimethoxybenzoate
TRAM-34: 1-[2-Chlorophenyl)diphenylmethyl]-1H-pyrazole
U-37883A: 4-Morpholinecarboximidine-N-1-adamantyl-N′ -1-cyclohexyl
UCL 1684: 6,10-Diaza-3(1,3),8(1,4)-dibenzena-1,5(1,4)-diquinolinacyclodecaphane
UK 78282: 4-[(Diphenylmethoxy)methyl]-1-[3-(4-methoxyphenyl)propyl]-piperidine
WIN 17317-3: (1-Benzyl-7-chloro-4-n-propylimino-1,4-dihydroquinoline
XE991: 10,10-bis(4-Pyridinylmethyl)-9-(10H)-anthracenone
ZD 6169: (S)-N-(4-Benzoyl-phenyl)-3,3,3-trifluoro-2-hydroxy-2-methylpropionamide
ZM 181,037: (R*,R*)-2-[2-[2-(Dimethylamino)-1-[5-(1,1-dimethylethyl)-2-methoxyphenyl]-1-hydroxypropyl]phenoxy]-acetamide
ZM 226600: N-(4-Phenylsulphonylphenyl)-3,3,3-trifluoro-2-hydroxy-2-methylpropanamide

Materials
Loading

References

1.
Ahluwalia J, Tinker A, Clapp LH, Duchen MR, Abramov AY, Pope S, Nobles M, Segal AW. 2004. The large-conductance Ca2+-activated K+ channel is essential for innate immunity. Nature. 427(6977):853-858. http://dx.doi.org/10.1038/nature02356
2.
Cohen BE, Grabe M, Jan LY. 2003. Answers and Questions from the KvAP Structures. Neuron. 39(3):395-400. http://dx.doi.org/10.1016/s0896-6273(03)00472-0
3.
Cooper EC, Jan LY. 2003. M-Channels. Arch Neurol. 60(4):496. http://dx.doi.org/10.1001/archneur.60.4.496
4.
D?Amico M, Gasparoli L, Arcangeli A. 2012. Potassium Channels: Novel Emerging Biomarkers and Targets for Therapy in Cancer. PRA. 8(1):53-65. http://dx.doi.org/10.2174/1574892811308010053
5.
Grgic I, Kaistha BP, Hoyer J, Köhler R. Endothelial Ca2+-activated K+ channels in normal and impaired EDHF-dilator responses - relevance to cardiovascular pathologies and drug discovery. 157(4):509-526. http://dx.doi.org/10.1111/j.1476-5381.2009.00132.x
6.
Jenkinson DH. Potassium channels - multiplicity and challenges. 147(S1):S63-S71. http://dx.doi.org/10.1038/sj.bjp.0706447
7.
Jiang Y, Lee A, Chen J, Cadene M, Chait BT, MacKinnon R. 2002. The open pore conformation of potassium channels. Nature. 417(6888):523-526. http://dx.doi.org/10.1038/417523a
8.
Jiang Y, Ruta V, Chen J, Lee A, MacKinnon R. 2003. The principle of gating charge movement in a voltage-dependent K+ channel. Nature. 423(6935):42-48. http://dx.doi.org/10.1038/nature01581
9.
Mackie AR, Byron KL. 2008. Cardiovascular KCNQ (Kv7) Potassium Channels: Physiological Regulators and New Targets for Therapeutic Intervention. Mol Pharmacol. 74(5):1171-1179. http://dx.doi.org/10.1124/mol.108.049825
10.
Petkov GV. 2012. Role of potassium ion channels in detrusor smooth muscle function and dysfunction. Nat Rev Urol. 9(1):30-40. http://dx.doi.org/10.1038/nrurol.2011.194
11.
Robbins J. 2001. KCNQ potassium channels: physiology, pathophysiology, and pharmacology. Pharmacology & Therapeutics. 90(1):1-19. http://dx.doi.org/10.1016/s0163-7258(01)00116-4
12.
Sadja R, Alagem N, Reuveny E. 2003. Gating of GIRK Channels. Neuron. 39(1):9-12. http://dx.doi.org/10.1016/s0896-6273(03)00402-1
13.
Schwarz JR, Bauer CK. 2004. Functions of erg K+channels in excitable cells. J Cellular Mol Med. 8(1):22-30. http://dx.doi.org/10.1111/j.1582-4934.2004.tb00256.x
14.
Seino S, Miki T. 2003. Physiological and pathophysiological roles of ATP-sensitive K+ channels. Progress in Biophysics and Molecular Biology. 81(2):133-176. http://dx.doi.org/10.1016/s0079-6107(02)00053-6
15.
Stocker M. 2004. Ca2+-activated K+ channels: molecular determinants and function of the SK family. Nat Rev Neurosci. 5(10):758-770. http://dx.doi.org/10.1038/nrn1516
16.
Talley EM, Sirois JE, Lei Q, Bayliss DA. 2003. Two-Pore-Domain (Kcnk) Potassium Channels: Dynamic Roles in Neuronal Function. Neuroscientist. 9(1):46-56. http://dx.doi.org/10.1177/1073858402239590
17.
Trimmer JS, Rhodes KJ. 2004. Localization of Voltage-Gated Ion Channels IN Mammalian Brain. Annu. Rev. Physiol.. 66(1):477-519. http://dx.doi.org/10.1146/annurev.physiol.66.032102.113328

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.